Intelligent Bio Solutions to submit FDA 510(k) in H2 2026
The company resolved all cybersecurity and software review items, de-risking the regulatory path for its fingerprint drug test. The move positions INBS for U.S. market entry into a multi-billion-dollar industry.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day